The United Laboratories International Holdings Limited

中/EN
中文繁體 English
  • Investor Relations
    IR Home Corporate Overview Financial Highlights Financial Reports ESG Reports Regulatory Filings Press Releases Company Presentations Stock Quotes & Charts Analyst Coverage FAQs IR Contact
  • Corporate
Investor Relations
  • IR Home
  • Corporate Overview
  • Financial Highlights
  • Financial Reports
  • ESG Reports
  • Regulatory Filings
  • Press Releases
  • Company
    Presentations
  • Stock Quotes &
    Charts
  • Analyst Coverage
  • FAQs
  • IR Contact

Press Releases

2009
Please select
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
DEC
13
TUL Obtained Products Approval for Recombinant Human Insulin Product, Full Sights on the Multi-billion Market
NOV
13
TUL Obtained Products Approval for Two New Eye Drops Products
NOV
10
TUL Acquired FDA Approval for its Product, Planned to Enter US Market
SEP
09
The Group Recorded the Highest Ever Sales of HK$2.1B, Capture Opportunities Arising from National Policies to Foster Long Term Growth
MAY
04
New Medicine Specializes in Treatment of Influenza Virus Type A Obtained Production Approval
APR
19
Market Launch of Acetaminophen and Dextromethorphan Hydrobromide Oral Solution - New Medicine Specializes in Treatment of Influenza and Cough
APR
08
The United Laboratories International Holdings Limited Announces 2008 Annual Results
MAR
23
TUL's Products Acquired International Standard Accreditation Once Again Granted EU Certificate of Suitability
Disclaimer | Sitemap

Copyright © 2019 The United Laboratories International Holdings Limited. All rights reserved.